Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.
Several other research firms have also recently commented on AQST. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Citigroup restated an "outperform" rating on shares of Aquestive Therapeutics in a report on Thursday, October 9th. Piper Sandler lifted their price target on Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an "overweight" rating in a report on Friday, November 7th. JMP Securities boosted their price target on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the company a "market outperform" rating in a research report on Thursday, October 9th. Finally, Zacks Research raised shares of Aquestive Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Friday, October 17th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $8.83.
Read Our Latest Research Report on AQST
Aquestive Therapeutics Trading Down 6.6%
NASDAQ:AQST opened at $2.95 on Friday. The company has a market cap of $359.90 million, a P/E ratio of -4.15 and a beta of 1.66. Aquestive Therapeutics has a twelve month low of $2.12 and a twelve month high of $7.55. The company's 50-day moving average price is $5.26 and its 200-day moving average price is $5.20.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). The business had revenue of $12.81 million for the quarter, compared to the consensus estimate of $12.94 million. On average, analysts expect that Aquestive Therapeutics will post -0.46 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of AQST. Pictet Asset Management Holding SA acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter valued at about $94,000. Arizona State Retirement System acquired a new position in shares of Aquestive Therapeutics in the 4th quarter worth approximately $184,000. Arcataur Capital Management LLC purchased a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $239,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Aquestive Therapeutics in the 4th quarter valued at approximately $420,000. Finally, MBM Wealth Consultants LLC acquired a new stake in Aquestive Therapeutics in the 4th quarter valued at approximately $109,000. Hedge funds and other institutional investors own 32.45% of the company's stock.
About Aquestive Therapeutics
(
Get Free Report)
Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.
The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aquestive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aquestive Therapeutics wasn't on the list.
While Aquestive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
